Qed Therapeutics, A Bridgebio Company

This study tests an oral medication called infigratinib in infants and children under 3 years old with achondroplasia, the most common form of dwarfism. The goal is to see if the drug can safely improve growth and body proportions. The trial involves different phases to find the …

This study follows 150 children aged 2.5 to 17 with hypochondroplasia, a condition causing short stature. Researchers will measure growth rates, body proportions, thinking skills, and quality of life over time. No treatments are given; the goal is to better understand the conditi…